RESUMEN
Respiratory diseases represent a major healthcare burden worldwide. Lung transplantation (LTx) is the "gold standard" for end-stage patients, strongly limited by shortage of available/suitable donor lungs. Normothermic ex vivo lung perfusion (EVLP) has significantly increased the number of lungs suitable for transplantation. Steen solution is used for EVLP, but the mechanisms involved in its beneficial properties remain to be clarified. We investigated the effects of Steen solution in an in vitro protocol of cold starvation and normothermic recovery on human lung spheroids, named pneumospheres (PSs), containing epithelial/basal cells, and on endothelial human umbilical vein endothelial cells (HUVEC). Steen solution significantly preserved the viability of PSs, reduced reactive oxygen species (ROS) release by PSs and HUVECs, decreased NADPH-oxidase (NOX) activity in PSs, and reduced inflammatory cytokines expression levels in HUVECs. Steen solution was able to specifically reduce NADPH oxidase 2 (NOX2) isoform activation, particularly in PSs, as detected by soluble-NOX2 peptide and p47-phosphorylation. Interestingly, a specific NOX2 inhibitor could partly mimic the pro-survival effect of Steen on PSs. We provide the first evidence that Steen solution can preserve lung epithelial/progenitor cells viability partially through NOX2 downregulation, and exert antioxidant effects on parenchymal cells, with consequent ROS reduction. These results suggest that NOX2 inhibition might be an additional strategy to reduce cellular damage during LTx procedures.
Asunto(s)
Antioxidantes/farmacología , Células Endoteliales de la Vena Umbilical Humana/efectos de los fármacos , Soluciones Isotónicas/farmacología , Pulmón/efectos de los fármacos , Soluciones Preservantes de Órganos/farmacología , Preservación de Órganos/métodos , Esferoides Celulares/efectos de los fármacos , Adolescente , Adulto , Células Cultivadas , Citoprotección , Femenino , Células Endoteliales de la Vena Umbilical Humana/metabolismo , Humanos , Pulmón/metabolismo , Masculino , NADPH Oxidasa 2/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Daño por Reperfusión/prevención & control , Esferoides Celulares/metabolismo , Adulto JovenRESUMEN
MicroRNAs (miRNAs) are small (typically 22 nucleotides) non-coding, endogenous, single-stranded RNAs. MiRNA genes are evolutionarily conserved and are located within the introns or exons of protein-coding genes, as well as in intergenic areas. Before the discovery of miRNAs, it had been known that a large part of the genome is not translated into proteins. This so called "junk" DNA was thought to be evolution debris with no function. Recently, the explosive research in this area has established miRNAs as powerful regulators of gene expression. While only about 1,424 human miRNA sequences have been identified so far, genomic computational analysis indicates that as many as 50,000 miRNAs may exist in the human genome, and each may have multiple targets based on similar sequences in the 3'-UTR of mRNA. MiRNAs have been implicated in different areas such as the immune response, neural development, DNA repair, apoptosis, oxidative stress response and others and it is impressive the list of diseases which have recently been found to be associated with abnormal miRNA expression. Here, we focus our attention on the importance of cancer regulator miRNAs. They are divided into oncomiRs and anti-oncomiRs that negatively regulate tumor suppressor genes and oncogenes, respectively. Importantly, the association of miRNAs with cancer has prompted additional functional classification of these short RNAs and their potential relevance in cancer diagnosis, prognosis and treatment.
Asunto(s)
Regulación Neoplásica de la Expresión Génica/genética , MicroARNs/genética , Neoplasias/diagnóstico , Neoplasias/terapia , Animales , Humanos , MicroARNs/metabolismo , Neoplasias/genética , PronósticoRESUMEN
Anticancer drug-induced tumor suppression may involve mechanisms of protection against neoplastic transformation that are normally latent in mammalian cells and consist in a genetic program implemented during anti-tumoral defense. This defense program results in the self elimination of cells harboring potentially dangerous mutations by triggering cell death through apoptosis and/or autophagy or in the execution of a program that leads to a permanent growth arrest known as senescence. These responses are considered crucial tumor suppressive mechanisms and their study appears to be essential to develop therapeutical procedures based on the enhancement of the different responses. This review summarizes fundamental knowledge on the underlying mechanisms able to limit excessive or aberrant cellular proliferation and on the prognostic value of both apoptosis and senescence detection. In addition, interesting evidence showing that different drugs induce senescence or cell death depending on the genetic features of the tumor cells as well as on the integrity of the relative pathways is reported.
Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias/tratamiento farmacológico , Transducción de Señal , Antineoplásicos/química , Antineoplásicos/farmacología , Muerte Celular/efectos de los fármacos , Telómero/efectos de los fármacos , Resultado del TratamientoRESUMEN
This study reports the immunomodulatory activity on human monocyte derived dendritic cells (MDDCs) of a vaccine preparation shown to be effective against an HPV16-related tumour in an animal model. The vaccine is composed of extract from Nicotiana benthamiana leaves containing HPV16 E7 protein expressed by a potato virus X-derived vector (NbPVX-E7). The effect of the extract was evaluated on MDDC differentiation and maturation by monitoring the phenotypic expression of specific markers. The results show that NbPVX-E7 does not induce monocyte differentiation to dendritic cells, but does induce MDDC maturation. Plant extract does not influence MDDC-uptake of E7-FITC while it significantly improves the Ovalbumin-FITC uptake, considered as a model antigen. Importantly, NbPVX-E7-pulsed MDDCs/PBMCs are able to prime human blood-derived lymphocytes from healthy individuals to induce HPV16 E7-specific cytotoxic activity. This is a propaedeutic study for a possible use of E7-containing plant extract in human immunotherapy of HPV-related lesions.
Asunto(s)
Adyuvantes Inmunológicos/farmacología , Células Dendríticas/inmunología , Linfocitos/inmunología , Nicotiana/metabolismo , Proteínas Oncogénicas Virales/inmunología , Vacunas contra Papillomavirus/inmunología , Extractos Vegetales/inmunología , Plantas Modificadas Genéticamente , Adyuvantes Inmunológicos/aislamiento & purificación , Presentación de Antígeno , Diferenciación Celular , Línea Celular Tumoral , Supervivencia Celular , Técnicas de Cocultivo , Citotoxicidad Inmunológica , Células Dendríticas/efectos de los fármacos , Células Dendríticas/metabolismo , Relación Dosis-Respuesta a Droga , Vectores Genéticos , Humanos , Activación de Linfocitos , Linfocitos/efectos de los fármacos , Masculino , Proteínas Oncogénicas Virales/biosíntesis , Proteínas Oncogénicas Virales/genética , Proteínas Oncogénicas Virales/aislamiento & purificación , Ovalbúmina/inmunología , Ovalbúmina/metabolismo , Proteínas E7 de Papillomavirus , Vacunas contra Papillomavirus/biosíntesis , Vacunas contra Papillomavirus/genética , Vacunas contra Papillomavirus/aislamiento & purificación , Extractos Vegetales/aislamiento & purificación , Hojas de la Planta , Potexvirus/genética , Proteínas Recombinantes/inmunología , Factores de Tiempo , Nicotiana/genéticaRESUMEN
Interferon (IFN) was the first cytokine produced by recombinant DNA technology used in wide-spread clinical treatment of infectious diseases as well as malignancies. The IFN clinical potential was clearly realized from the outset. However, IFN represents one of the most controversial drugs of our time, as remarkable cycles of promise and disappointment have affected its development and use. Considerable evidence regarding anti-tumor activities of IFNs has been reported. In this paper we focus on molecular bases of the IFN system that may relate to its antitumor activities. Many of the numerous genes transcriptionally activated by IFNs have been shown to encode proteins that activate immune recognition of tumor cells, directly or indirectly exert tumor suppressor activity and/or control tumor cell cycle and programmed cell death. In addition, a physiological relevant function for endogenous type I IFN in cancer immunoediting process and a new way to IFN clinical use based on gene therapy or vaccine-like approaches have recently been suggested. The identification of selected tissue-specific and/or tumor-specific target pathways as well as of different type I IFN tumor escape and resistance mechanisms may provide novel approaches in the search for new IFN-based therapeutic strategies to circumvent cancer disease or improve clinical outcome. Promising IFN treatment has been recently defined by using novel pharmaceutical preparations with a more favourable pharmacokinetic response, also in combination with other bioreagents or other modalities of therapy. Translational research, linking both basic and clinical research, will lead to a new rationale for the use of IFN in cancer therapy.
Asunto(s)
Antineoplásicos/uso terapéutico , Terapia Biológica , Interferón Tipo I/uso terapéutico , Neoplasias/terapia , Animales , Humanos , Neoplasias/genética , Neoplasias/fisiopatología , Proteínas RecombinantesRESUMEN
Evidence has gathered that CD28 costimulation facilitates T cell activation by potentiating TCR intrinsic-signaling. However, the underlying molecular mechanism is largely unknown. Here we show that, by enhancing T cell/APC close contacts, CD28 facilitates TCR signal transduction. Moreover, the signal supplied by CD28 does not lead to increased Zap-70 and Lat phosphorylation, but amplifies PLCgamma1 activation and Ca(2+) response. We provide evidence that the PTK Itk controls the latter function. Our data suggest that CD28 binding to B7 contributes to setting the level of TCR-induced phosphorylated Lat for recruiting signaling complexes, whereas the CD28 signal boosts multiple pathways by facilitating PLCgamma1 activation. These results should provide a conceptual framework for understanding quantitative and qualitative aspects of CD28-mediated costimulation.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales , Antígenos CD28/fisiología , Activación de Linfocitos/fisiología , Proteínas de la Membrana , Proteínas Nucleares , Receptores de Antígenos de Linfocitos T/inmunología , Transducción de Señal/fisiología , Células Presentadoras de Antígenos/inmunología , Antígeno B7-1/inmunología , Antígenos CD28/química , Antígenos CD28/genética , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/metabolismo , Señalización del Calcio/fisiología , Proteínas Portadoras/metabolismo , Línea Celular , Proteínas de Unión al ADN/metabolismo , Activación Enzimática , Regulación de la Expresión Génica/fisiología , Humanos , Interleucina-2/biosíntesis , Interleucina-2/genética , Isoenzimas/metabolismo , Células Jurkat/inmunología , Sustancias Macromoleculares , Factores de Transcripción NFATC , Fosfatidilinositol 3-Quinasas/metabolismo , Fosfolipasa C gamma , Fosfoproteínas/metabolismo , Fosforilación , Fosfotirosina/química , Procesamiento Proteico-Postraduccional , Proteínas Tirosina Quinasas/metabolismo , Proteínas Recombinantes de Fusión/inmunología , Eliminación de Secuencia , Factores de Transcripción/metabolismo , Transfección , Fosfolipasas de Tipo C/metabolismo , Proteína Tirosina Quinasa ZAP-70RESUMEN
The mechanism through which CD28 costimulation potentiates TCR-driven gene expression is still not clearly defined. Vav-1, an exchange factor for Rho GTPases thought to regulate, mainly through Rac-1, various signaling components leading to cytokine gene expression, is tyrosine phosphorylated upon CD28 engagement. Here, we provide evidence for a key role of Vav-1 in CD28-mediated signaling. Overexpression of Vav-1 in Jurkat cells in combination with CD28 ligation strongly reduced the concentration of staphylococcus enterotoxin E/MHC required for TCR-induced NF-AT activation. Surprisingly, upon Vav-1 overexpression CD28 ligation sufficed to activate NF-AT in the absence of TCR engagement. This effect was not mediated by overexpression of ZAP-70 nor of SLP-76 but necessitated the intracellular tail of CD28, the intactness of the TCR-proximal signaling cascade, the Src-homology domain 2 (SH2) domain of Vav-1, and SLP-76 phosphorylation, an event which was favored by Vav-1 itself. Cells overexpressing Vav-1 formed lamellipodia and microspikes reminiscent of Rac-1 and Cdc42 activation, respectively, for which the SH2 domain of Vav-1 was dispensable. Together, these data suggest that CD28 engagement activates Vav-1 to boost TCR signals through a synergistic cooperation between Vav-1 and SLP-76 and probably via cortical actin changes to facilitate the organization of a signaling zone.
Asunto(s)
Adyuvantes Inmunológicos/fisiología , Antígenos CD28/fisiología , Proteínas de Ciclo Celular , Proteínas de Unión al ADN/metabolismo , Proteínas Nucleares , Proteínas Proto-Oncogénicas/fisiología , Receptores de Antígenos de Linfocitos T alfa-beta/fisiología , Transducción de Señal/inmunología , Factores de Transcripción/metabolismo , Proteínas Adaptadoras Transductoras de Señales , Adyuvantes Inmunológicos/metabolismo , Antígenos CD28/metabolismo , Humanos , Células Jurkat , Factores de Transcripción NFATC , Fosfoproteínas/biosíntesis , Fosfoproteínas/metabolismo , Fosfoproteínas/fisiología , Fosforilación , Proteínas Tirosina Quinasas/biosíntesis , Proteínas Tirosina Quinasas/fisiología , Proteínas Proto-Oncogénicas/biosíntesis , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas c-vav , Seudópodos/inmunología , Seudópodos/metabolismo , Transfección , Proteína Tirosina Quinasa ZAP-70 , Dominios Homologos src/inmunologíaRESUMEN
In this study, T or NK cell clones used as antigen-presenting cells (T- or NK-APC) were shown to be significantly less efficient than professional APC in inducing Th1 and Th2 cytokines by antigen-specific T cell clones. This phenomenon was not related to a limited engagement of TCR by T-APC, since comparable thresholds of TCR down-regulation were shown when antigen was presented by either T-APC or professional APC. Rather, the stimulatory T-APC weakness was due to their inability, because they are CD40-, to provide the appropriate co-stimuli to responder T cells both indirectly via IL-12, and partially via direct CD40L triggering on T cells. Indeed, the simultaneous addition of IL-12 and reagents directly engaging CD40L on responder T cells restored T cell cytokine synthesis when antigen was presented by T-APC. In addition, either IL-12 production or blocking of T cell cytokine synthesis by anti-IL-12 p75 antibodies was evident only when professional APC were used in our antigen-specific system. The down-regulation of cytokine synthesis in the system of T-T cell presentation could represent a novel mechanism of immune regulation, which may intervene to switch off detrimental Th1- or Th2-mediated responses induced by antigen presentation among activated T cells infiltrating inflamed tissues.
Asunto(s)
Células Presentadoras de Antígenos/fisiología , Antígenos CD40/fisiología , Citocinas/biosíntesis , Activación de Linfocitos , Glicoproteínas de Membrana/fisiología , Células TH1/fisiología , Células Th2/fisiología , Antígenos CD/fisiología , Antígeno B7-1/fisiología , Antígeno B7-2 , Ligando de CD40 , Células Cultivadas , Humanos , Interleucina-12/farmacología , Receptores de Antígenos de Linfocitos T/fisiologíaRESUMEN
Interferons (IFNs) are able to induce an increased transcription of several genes, which can occur within minutes of the binding of IFNs to their receptors. The specific induced transcription is mediated by the interaction of specific transcription factors with regulatory DNA sequences that lie upstream the promoters of IFN induced genes. Phosphorylation of IFN-specific transcription factors is required for activation of transcription. We have studied the antiviral effect and the induction of gene expression by IFN-alpha in Friend Leukemia cells (FLC) in the presence of a series of inhibitors of known kinases. Protein kinase C (PKC)-specific inhibitors, i.e. calphostin C and bisindolylmaleimide, failed to influence the IFN-induced gene expression and the antiviral state. Likewise, little or no effect was found using inhibitors such as H7 or K252a. Chronic exposure of FLC to phorbol ester, that causes down regulation of PKC (the effectiveness of TPA treatment was proven by PKC enzymatic assay), has no effect on IFN-alpha action. In addition, treatment of FLC with staurosporine prevented the induction of IFN-stimulated genes and the establishment of the antiviral state only when this drug was used at high dosage (500 nM). This result indicates that, also in FLC, activation of PKC is not involved in the transcriptional response of the cells to IFN-alpha treatment. The non receptor tyrosine kinases of the JAK family that take part in the IFNs-specific transduction pathways could be the target of the staurosporine specific inhibition of the IFN-alpha action.